Intravenous busulfan with thiotepa and cyclophosphamide (TBC) as a conditioning regimen for autologous progenitor cell transplantation (PCT) in patients with multiple myeloma (MM).

被引：0
|
作者：
Anagnostopoulos, A [1 ]
Aleman, A [1 ]
Weber, D [1 ]
Andersson, B [1 ]
Braunschweig, I [1 ]
Claxton, D [1 ]
Donato, M [1 ]
Khouri, I [1 ]
Anderlini, P [1 ]
Korbling, M [1 ]
Gajewski, J [1 ]
Alexanian, R [1 ]
Champlin, R [1 ]
Giralt, S [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Dept Blood & Marrow Transplantat, Houston, TX 77030 USA
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1497
引用
下载
收藏
页码：335A / 335A
页数：1
相关论文
共 50 条
  • [31] Toxicity and early response after single daily dose of intravenous busulfan and melphalan as conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma
    Blanes, Margarita
    De la Rubia, Javier
    Lahuerta, Juan J.
    Gonzalez, Juan D.
    Ribas, Paz
    Solano, Carlos
    Sanz, Miguel A.
    BLOOD, 2007, 110 (11) : 307B - 307B
  • [32] Efficacy of olanzapine-containing prophylactic antiemetic regimen in autologous hematopoietic stem cell transplantation patients who undergo conditioning with thiotepa, busulfan and cyclophosphamide
    Jung, Youree
    Kim, Bobae
    Shin, Eunjeong
    Suh, Sungyun
    Cho, Yoonsook
    Lee, Juyeun
    Koh, Youngil
    BONE MARROW TRANSPLANTATION, 2018, 53 : 323 - 323
  • [33] Thiotepa, Busulfan, Cyclophosphamide: Effective but Toxic Conditioning Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation in Central Nervous System Lymphoma
    Delphine, Lebon
    Pierre-Edouard, Debureaux
    Bruno, Royer
    Berengere, Gruson
    Magalie, Joris
    Patrick, Votte
    Jean-Pierre, Marolleau
    Pierre, Morel
    MEDICAL SCIENCES, 2023, 11 (01)
  • [34] High dose melphalan (HDM) is superior to cyclophosphamide plus etoposide and busulfan (CVB) as the conditioning regimen in autologous stem cell transplantation for multiple myeloma
    谷景立
    China Medical Abstracts (Internal Medicine), 2019, 36 (04) : 230 - 231
  • [35] Safety and Efficacy of Targeted-Dose Busulfan and Bortezomib as a Conditioning Regimen for Patients with Relapsed Multiple Myeloma Undergoing a Second Autologous Blood Progenitor Cell Transplantation
    Freytes, Cesar O.
    Toro, Juan J.
    Yeh, Rosa F.
    Stadtmauer, Edward A.
    Ratanatharathorn, Voravit
    Akpek, Goerguen
    Sahovic, Entezam
    Tricot, Guido J.
    Shaughnessy, Paul J.
    White, Darrell J.
    Rodriguez, Tulio E.
    Solomon, Scott R.
    Yu, Louie H.
    Zhao, Cathy
    Patil, Shiva
    Armstrong, Elizabeth
    Smith, Angela
    Elekes, Agnes
    Kato, Kazunobu
    Reece, Donna E.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (12) : 1949 - 1957
  • [36] Busulfan and melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma
    Jung, Sung-Hoon
    Lee, Je-Jung
    Kim, Jin Seok
    Min, Chang-Ki
    Kim, Kihyun
    Choi, Yunsuk
    Eom, Hyeon-Seok
    Joo, Young Don
    Kim, Sung-Hyun
    Kwak, Jae-Yong
    Kang, Hye Jin
    Lee, Jae Hoon
    Lee, Ho Sup
    Mun, Yeung-Chul
    Moon, Joon Ho
    Sohn, Sang Kyun
    Park, Seong Kyu
    Park, Yong
    Shin, Ho-Jin
    Yoon, Sung-Soo
    BONE MARROW TRANSPLANTATION, 2018, 53 : 262 - 263
  • [37] Intravenous busulfan and melphalan as conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-based approach
    Blanes, M.
    Lahuerta, J. J.
    Gonzalez, J. D.
    Ribas, P.
    Solano, C.
    Alegre, A.
    Blade, J.
    San Miguel, J. F.
    Sanz, M. A.
    de la Rubia, J.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S330 - S331
  • [38] Matched pair analysis of intravenous busulfan and melphalan vs. melphalan alone as conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation
    de la Rubia, J.
    Lahuerta, J. J.
    Gonzalez, J. D.
    Ribas, P.
    Solano, C.
    Blade, J.
    San Miguel, J. F.
    Sanz, M. A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 192 - 192
  • [39] Once daily intravenous busulfan as part of a busulfan/cyclophosphamide conditioning regimen for allogeneic hematopoietic stem cell transplantation
    Mates, M
    Michalska, H
    Hasegawa, W
    Kiss, T
    Daly, A
    Loach, D
    Messner, H
    Lipton, J
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2004, 10 (02) : 36 - 36
  • [40] BUSULFAN AND CYCLOPHOSPHAMIDE HAS SIMILAR OUTCOMES TO HIGH DOSE MELPHALAN AS A PREPARATIVE REGIMEN FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA
    Mahindra, A.
    Bolwell, B.
    Rybicki, L.
    Dean, R.
    Poblman, B.
    Sobecks, R.
    Andresen, S.
    Sweetenbam, J.
    Kalaycio, M.
    Copelan, E.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (02) : 69 - 69
12345